The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Correspondence
PreviousPrevious
Volume 346:2088-2089 June 27, 2002 Number 26
NextNext

Bisphosphonates and Osteoporosis

Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF
-PDA Full Text
-Purchase this article

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-Related Article
 by Reid, I. R.
-PubMed Citation
To the Editor: The prospect of a quick fix for the problem of postmenopausal osteoporosis by means of intermittent administration of intravenous bisphosphonate is exciting. Reid et al. (Feb. 28 issue)1 report that bone mineral density was increased for up to one year after intermittent intravenous therapy with zoledronic acid. The authors do not discuss the rate of nonvertebral fractures, which, if anything, was higher in the treated group than in the placebo group. The authors do point out that all the women in their study had base-line bone-mineral-density values that were high enough that therapy would not have been . . . [Full Text of this Article]


This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.